LSEG’s Rhiannon Main speaks to Bob Rauker, Belluscura’s Chief Executive Officer, to discuss how the MedTech company’s impressive growth in treating COPD and lung diseases with its next-generation oxygen enrichment technologies. 

Having seen an oversubscribed IPO in 2021, the conversation highlights the company’s journey since its formation; from the first product launch, to FDA approval, continuing innovation, and how listing on AIM enabled a successful raise and has unlocked new growth potential. 

To watch more from this series, head to lsegissuerservices.com/spark